Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERYPNASDAQ:HUMANASDAQ:ITOSNASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AHUMAHumacyte$2.36+1.3%$1.97$1.15▼$9.79$361.43M23.85 million shs2.04 million shsITOSiTeos Therapeutics$10.00-0.2%$8.12$4.80▼$18.13$383.50M1.51675,763 shs650,936 shsSLDBSolid Biosciences$4.65+0.9%$3.38$2.41▼$10.37$357.35M2.221.16 million shs1.07 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%HUMAHumacyte-3.32%-12.73%+4.02%-29.61%-62.36%ITOSiTeos Therapeutics-0.79%-0.10%+28.30%+43.97%-34.30%SLDBSolid Biosciences-8.17%-4.55%+66.43%-4.36%-38.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AHUMAHumacyte2.4328 of 5 stars3.51.00.00.02.62.50.6ITOSiTeos Therapeutics3.6032 of 5 stars4.14.00.00.01.63.30.6SLDBSolid Biosciences3.6224 of 5 stars4.63.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERYPERYTECH Pharma 0.00N/AN/AN/AHUMAHumacyte 3.00Buy$11.71396.37% UpsideITOSiTeos Therapeutics 2.14Hold$15.8658.57% UpsideSLDBSolid Biosciences 3.23Buy$14.90220.43% UpsideCurrent Analyst Ratings BreakdownLatest ERYP, HUMA, ITOS, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/6/2025SLDBSolid BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.005/28/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.005/28/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$10.00 ➝ $12.005/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/16/2025SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.005/16/2025SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.005/16/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.005/14/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88HUMAHumacyte$1.57M233.17N/AN/A($0.41) per share-5.76ITOSiTeos Therapeutics$35M10.93N/AN/A$16.16 per share0.62SLDBSolid Biosciences$8.09M44.55N/AN/A$3.43 per share1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AHUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)ITOSiTeos Therapeutics-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)Latest ERYP, HUMA, ITOS, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERYPERYTECH PharmaN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERYPERYTECH Pharma0.323.653.65HUMAHumacyte0.363.683.28ITOSiTeos TherapeuticsN/A14.1314.13SLDBSolid BiosciencesN/A10.8910.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERYPERYTECH Pharma1.09%HUMAHumacyte44.71%ITOSiTeos Therapeutics97.16%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipERYPERYTECH Pharma1.94%HUMAHumacyte5.10%ITOSiTeos Therapeutics12.50%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableHUMAHumacyte150155.12 million147.21 millionOptionableITOSiTeos Therapeutics9038.27 million33.49 millionOptionableSLDBSolid Biosciences10077.51 million76.04 millionOptionableERYP, HUMA, ITOS, and SLDB HeadlinesRecent News About These CompaniesSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesJune 18 at 11:39 AM | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC WainwrightJune 17 at 8:34 AM | marketbeat.comSolid Biosciences Approves Equity Plan Amendment at MeetingJune 13, 2025 | tipranks.comAnalysts Offer Predictions for SLDB FY2026 EarningsJune 11, 2025 | americanbankingnews.comBrokers Offer Predictions for SLDB FY2026 EarningsJune 10, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Two Sigma Investments LPJune 9, 2025 | marketbeat.comSolid Biosciences' (SLDB) Market Outperform Rating Reaffirmed at JMP SecuritiesJune 8, 2025 | americanbankingnews.comSolid Biosciences' (SLDB) "Market Outperform" Rating Reiterated at JMP SecuritiesJune 6, 2025 | marketbeat.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest UpdateJune 3, 2025 | marketbeat.comMillennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)June 1, 2025 | marketbeat.comSolid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthroughMay 28, 2025 | investing.comSolid Biosciences to Participate at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by BrokeragesMay 28, 2025 | marketbeat.comResearch Analysts Set Expectations for SLDB FY2025 EarningsMay 27, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor FitzgeraldMay 24, 2025 | marketbeat.comChardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock PriceMay 21, 2025 | marketbeat.comQ1 Earnings Forecast for SLDB Issued By William BlairMay 21, 2025 | marketbeat.comTruist maintains buy on Solid Biosciences stock, price target at $16May 18, 2025 | investing.comDimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)May 18, 2025 | marketbeat.comWhen Might Solid Biosciences Run Out Of Money?May 17, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesERYP, HUMA, ITOS, and SLDB Company DescriptionsERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Humacyte NASDAQ:HUMA$2.36 +0.03 (+1.29%) Closing price 04:00 PM EasternExtended Trading$2.38 +0.02 (+0.85%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.iTeos Therapeutics NASDAQ:ITOS$10.00 -0.02 (-0.20%) Closing price 04:00 PM EasternExtended Trading$10.01 +0.01 (+0.05%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Solid Biosciences NASDAQ:SLDB$4.65 +0.04 (+0.87%) Closing price 04:00 PM EasternExtended Trading$4.83 +0.18 (+3.87%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
